GLP-1 agonists, including exenatide, liraglutide, lixisenatide, albiglutide, and taspoglutide can stimulate insulin secretion (similar to other insulin secretagogues), improve peripheral insulin resistance, decrease body weight, and reduce the risk of hypoglycemia for Type 2 diabetic patients [63]. Here, INS is linked to type 2 diabetes mellitus.